Middle East Pharmaceutical Industries Company vs Zoetis Inc.
A head-to-head of Middle East Pharmaceutical Industries Company (4016) and Zoetis Inc. (ZTS) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4016 | ZTS |
|---|---|---|
| Market Cap | 2.06B SAR | $32.10B |
| P/E (TTM) | 12.46 | 12.70 |
| Forward P/E | 11.57 | 10.36 |
| P/S | 4.19 | 3.64 |
| P/B | 5.07 | 11.89 |
| EV/EBITDA | 9.59 | 10.32 |
| Dividend Yield | 2.39% | 2.31% |
| Profit Margin | 21.19% | 27.79% |
| Gross Margin | 62.29% | 71.84% |
| Operating Margin | 23.74% | 38.00% |
| Revenue Growth (YoY) | +33.65% | +2.91% |
| FCF Yield | 1.62% | 6.44% |
| Debt / Equity | 19.87 | 279.77 |
| Current Ratio | 2.85 | 3.15 |
Which is better: Middle East Pharmaceutical Industries Company or Zoetis Inc.?
- ✓Larger by market cap: Zoetis Inc.
- ✓Cheaper valuation (lower P/E): Middle East Pharmaceutical Industries Company
- ✓Higher dividend yield: Middle East Pharmaceutical Industries Company
- ✓More profitable (net margin): Zoetis Inc.
- ✓Faster revenue growth: Middle East Pharmaceutical Industries Company
- ✓Higher free-cash-flow yield: Zoetis Inc.
Across 13 available metrics, Zoetis Inc. leads 7–6.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Middle East Pharmaceutical Industries Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.